U.S. Markets closed

CLASS ACTION UPDATE for COF, MGNX and MYGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / October 17, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Capital One Financial Corporation (COF)

Lawsuit on behalf of: investors who purchased February 2, 2018 - July 29, 2019
Lead Plaintiff Deadline : December 2, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/capital-one-financial-corporation-loss-form?prid=3959&wire=1

According to the filed complaint, during the class period, Capital One Financial Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company did not maintain robust information security protections, and its protection did not shield personal information against security breaches; (2) such deficiencies heightened the Company's exposure to a cyber-attack; and (3) as a result, Capital One's public statements were materially false and misleading at all relevant times.

MacroGenics, Inc. (MGNX)

Lawsuit on behalf of: investors who purchased February 6, 2019 - June 3, 2019
Lead Plaintiff Deadline : November 12, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/macrogenics-inc-loss-form?prid=3959&wire=1

According to the filed complaint, during the class period, MacroGenics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.

Myriad Genetics, Inc. (MYGN)

Lawsuit on behalf of: investors who purchased September 2, 2016 - August 13, 2019
Lead Plaintiff Deadline : November 26, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/myriad-genetics-inc-loss-form?prid=3959&wire=1

According to the filed complaint, during the class period, Myriad Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/563325/CLASS-ACTION-UPDATE-for-COF-MGNX-and-MYGN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders